Niraparib Approved for Advanced HRD-Positive Ovarian Cancer

The FDA has approved niraparib (Zejula®, Tesaro, Inc.) for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who experience disease progression following three or more lines of chemotherapy. Niraparib is indicated for patients whose tumors are positive for homologous recombination deficiency (HRD). The approval was based on QUADRA (NCT02354586), a multicenter, open-label, single-arm, phase 2 trial that enrolled 463 patients with relapsed, high-grade serous epithelial o...
Continue reading

Learning Needs: Checkpoint Inhibitors in Cervical Cancer

Pre-activity assessment data from i3 Health's continuing medical education (CME)/continuing nursing education (CNE) activity "Optimizing the Management of Advanced Cervical Cancer With Checkpoint Inhibitor Therapy" has revealed significant baseline knowledge gaps in the area of checkpoint inhibitor therapies for advanced cervical cancer. Three hundred and ninety-seven learners took part in the educational activity and completed the pre-activity assessment, and 375 of these finished the activity ...
Continue reading

Low Rates of Cancer Screening in Women With Diabetes

Because high blood insulin and insulin resistance are associated with increased cancer risk, cancer screening is especially important in patients with diabetes. However, a recent study has found that women with diabetes underutilize screening for breast, cervical, and colorectal cancer. Cancer screening has been shown to decrease the risk of death by up to 33% for breast cancer, 70% for cervical cancer, and 37% for colorectal cancer. By enabling early detection and treatment before the disease h...
Continue reading

Veliparib Adds Benefits to Ovarian Carcinoma Treatment: An Interview With Robert L. Coleman, MD

High-grade serous ovarian carcinoma is the most malignant form of ovarian cancer, with a high recurrence rate and a low survival rate. While patients are commonly treated with induction chemotherapy consisting of paclitaxel plus carboplatin, there is a need to develop additional first- and second-line therapies to increase survival in patients with this disease. In their study now published in The New England Journal of Medicine, Robert L. Coleman, MD, a Professor in the Department of Gynecologi...
Continue reading

Lenvatinib Plus Pembrolizumab Approved for Advanced Endometrial Carcinoma

The FDA has approved lenvatinib (Lenvima®, Eisai) plus pembrolizumab (Keytruda®, Merck) for patients with advanced endometrial carcinoma who experience disease progression after at least one prior systemic therapy but are ineligible for curative surgery or radiation. Lenvatinib/pembrolizumab is indicated for patients whose cancer is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). "Lenvatinib is a multikinase inhibitor of VEGFR1, VEGFR2, and VEGFR3, and other rece...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.